LUND, Sweden, May 26, 2020 /PRNewswire/ -- Immunovia invites
you to a teleconference (in English) for all stakeholders and media
on Wednesday, May 27, 2020 at
16:30 CET. Mats Grahn, CEO will present an update on the
company's COVID-19 response as well as an update on the activities
in preparation for the launch of IMMray™ PanCan-d and the
prospective studies followed by a Q&A session.
For the live call, please call in a few minutes in advance. To
attend, please dial-in at one of the numbers below and provide the
conference code Immunovia to the operator:
Conference Dial in numbers:
Sweden: +46-(0)-8-50520424
USA: +1-212-999 6659
Norway: +47-2-156 3318
Denmark: +45-3271-4573
France: +33-(0)-1-7099-4740
Netherlands:
+31-(0)-20-708-5073
Germany: +49-(0)-30-3001-90612
Finland: +358-9-2319-5437
Spain: +34-91-787-0777
Austria: +43-(0)-1-25349-78223
UK (Standard International Access): +44-(0)-20-3003-2666
Conference Code: Immunovia
Immunovia Webcast:
https://channel.royalcast.com/webcast/immunovia/20200527_1/
For more information, please contact:
Julie Silber
Director of Investor Relations, Immunovia
Email: julie.silber@immunovia.com
Tel: +46-7-93-486-277
There will be an MP3-file available at Immunovia's webpage under
Investors/Audio-Gallery
(https://immunovia.com/investors/audio-gallery/) for those who want
to listen to the telephone conference afterwards. The file will be
available within two hours after the conference has ended.
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently entering the final validation for sales start Q3
2020. When validated, IMMray™ PanCan-d will be the first
blood-based test for early diagnosis of pancreatic cancer on the
market, with a potential to significantly improve patient survival
and outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/invitation-to-immunovia-s-update--4-on-covid-19-company-response,c3119387
The following files are available for download:
https://mb.cision.com/Main/13121/3119387/1253231.pdf
|
Release
|